|Videos|April 15, 2022
Potential Use of Lu 177 Vipivotide Tetraxetan in Non-VISION Prostate Cancer Settings
Author(s)Scott Tagawa, MD, MS, FACP, FASCO
Scott Tagawa, MD, MS, FACP, discusses other prostate cancer settings besides metastatic CRPC where Lu 177 vipivotide tetraxetan could potentially be useful, and touches on ongoing clinical trials in these settings.
Advertisement
Episodes in this series
Advertisement
Related to this article
Updated guidance recommends biennial prostate-specific antigen testing for average-risk men aged 50 to 69 years and annual screening beginning at age 45 for higher-risk men.
NCCN prostate cancer guidelines now list the ArteraAI Prostate Test (Post-RP), an AI tool that stratifies metastasis risk in biochemical recurrence after prostatectomy.
Advertisement
Advertisement
Trending on Targeted Onc
1
Survey Highlights NMIBC Care Challenges Among US Military Service, Veterans
2
FDA Approves Durvalumab-EV Combo, Expanding MIBC Treatment Options
3
New ACS Guidelines Push for Earlier Prostate Cancer Screening
4
Temab-A Shows Promising Survival in Pretreated Nonsquamous NSCLC
5